Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Idelalisib + Otlertuzumab + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Idelalisib||Zydelig||CAL-101|GS-1101||PIK3CD inhibitor 24||Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24450857). Zydelig (idelalisib) is FDA approved for follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and in combination with Rituxan (rituximab) for relapsed chronic lymphocytic leukemia (FDA.gov).|
|Otlertuzumab||TRU-016|TRU016|TRU 016||CD37 Antibody 6||Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 11||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01644253||Phase I||Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab||Phase 1b Safety and Efficacy Study of TRU-016||Active, not recruiting|